Related Experiment Video
Updated: Apr 18, 2026

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025
A computational strategy to select optimized protein targets for drug development toward the control of cancer
Nicolas Carels1, Tatiana Tilli1, Jack A Tuszynski2
1Laboratório de Modelagem de Sistemas Biológicos, National Institute of Science and Technology for Innovation in Neglected Diseases (INCT/IDN, CNPq), Centro de Desenvolvimento Tecnológico em Saúde, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Abstract:
In this report, we describe a strategy for the optimized selection of protein targets suitable for drug development against neoplastic diseases taking the particular case of breast cancer as an example. We combined human interactome and transcriptome data from malignant and control cell lines because highly connected proteins that are up-regulated in malignant cell lines are expected to be suitable protein targets for chemotherapy with a lower rate of undesirable side effects. We normalized transcriptome data and applied a statistic treatment to objectively extract the sub-networks of down- and up-regulated genes whose proteins effectively interact. We chose the most connected ones that act as protein hubs, most being in the signaling network. We show that the protein targets effectively identified by the combination of protein connectivity and differential expression are known as suitable targets for the successful chemotherapy of breast cancer. Interestingly, we found additional proteins, not generally targeted by drug treatments, which might justify the extension of existing formulation by addition of inhibitors designed against these proteins with the consequence of improving therapeutic outcomes. The molecular alterations observed in breast cancer cell lines represent either driver events and/or driver pathways that are necessary for breast cancer development or progression. However, it is clear that signaling mechanisms of the luminal A, B and triple negative subtypes are different. Furthermore, the up- and down-regulated networks predicted subtype-specific drug targets and possible compensation circuits between up- and down-regulated genes. We believe these results may have significant clinical implications in the personalized treatment of cancer patients allowing an objective approach to the recycling of the arsenal of available drugs to the specific case of each breast cancer given their distinct qualitative and quantitative molecular traits.
Insights
This study identifies optimal protein targets for breast cancer chemotherapy by analyzing gene expression and protein interaction data. The findings reveal new therapeutic targets and personalized treatment strategies for improved patient outcomes.
Area of Science:
- Oncology
- Bioinformatics
- Molecular Biology
Background:
- Identifying effective protein targets is crucial for developing successful cancer chemotherapy with minimal side effects.
- Breast cancer, a complex neoplastic disease, exhibits diverse molecular subtypes necessitating tailored therapeutic strategies.
Purpose of the Study:
- To develop and validate a strategy for selecting optimal protein targets for drug development in neoplastic diseases, using breast cancer as a model.
- To identify novel protein targets beyond current treatments that could enhance therapeutic efficacy in breast cancer.
Main Methods:
- Integrated analysis of human interactome and transcriptome data from malignant and control cell lines.
- Normalization of transcriptome data and statistical analysis to identify differentially expressed and interacting gene sub-networks.
- Prioritization of highly connected proteins (hubs) within signaling networks as potential drug targets.
Main Results:
- The combined approach of protein connectivity and differential expression successfully identified known, effective chemotherapy targets for breast cancer.
- Several novel protein targets were identified, suggesting potential for expanding existing drug formulations to improve treatment outcomes.
- Predicted subtype-specific drug targets and compensatory regulatory circuits for luminal A, B, and triple-negative breast cancer subtypes.
Conclusions:
- The developed strategy offers an objective method for selecting protein targets for cancer drug development.
- Identified targets and subtype-specific insights hold significant potential for personalized cancer medicine and optimizing existing drug therapies.
- This approach facilitates the rational repurposing of drugs based on distinct molecular profiles of individual breast cancer subtypes.
More Related Videos
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
10:21Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024
Related Concept Videos
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets
Drug Discovery: Overview